Bone cancer pain (BCP) is still an intractable problem currently because the analgesic pharmacological
intervention remains insufficient. Thus, the development of novel therapeutic target is critical for the treatment of
BCP. Emerging evidence demonstrated that some chemokines and their receptors contribute to the induction and
maintenance of BCP. In this article, we reviewed the current evidence for the role of different chemokines and their
receptors (e.g. CXCL12/CXCR4, CXCL1/CXCR2, CCL2/CCR2, CCL5/CCR5, CX3CL1/CX3CR1 and
CXCL10/CXCR3) in mediating BCP. By extensively understanding the involvement of chemokines and their receptors
in BCP, novel therapeutic targets may be revealed for the treatment of BCP.